Pyxis Oncology, Inc.
PYXS
$3.37
-$0.63-15.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.54% | -11.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.07% | -2.29% | |||
| Operating Income | -19.46% | 14.88% | |||
| Income Before Tax | -21.76% | 14.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.88% | 13.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.88% | 13.25% | |||
| EBIT | -19.46% | 14.88% | |||
| EBITDA | -20.07% | 15.18% | |||
| EPS Basic | -18.66% | 14.48% | |||
| Normalized Basic EPS | -20.50% | 15.79% | |||
| EPS Diluted | -18.66% | 14.48% | |||
| Normalized Diluted EPS | -20.50% | 15.79% | |||
| Average Basic Shares Outstanding | 1.03% | 1.42% | |||
| Average Diluted Shares Outstanding | 1.03% | 1.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||